ONCT Stock Overview
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oncternal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.55 |
| 52 Week High | US$13.14 |
| 52 Week Low | US$5.57 |
| Beta | 1.37 |
| 1 Month Change | 4.08% |
| 3 Month Change | -4.74% |
| 1 Year Change | 44.39% |
| 3 Year Change | -93.53% |
| 5 Year Change | n/a |
| Change since IPO | -93.92% |
Recent News & Updates
Recent updates
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Oncternal: Solid Data In Tough-To-Treat Cancer
Jan 31Oncternal Therapeutics: Recent Success Points To A Bright Future
Jan 29Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary
Jan 14Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies
Jan 07Oncternal Therapeutics soars after presenting data at ASH
Dec 07Oncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M
Nov 18Shareholder Returns
| ONCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | 1.0% | 1.2% |
| 1Y | 44.4% | 0.7% | 24.9% |
Return vs Industry: ONCT exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: ONCT exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| ONCT volatility | |
|---|---|
| ONCT Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONCT has not had significant price volatility in the past 3 months.
Volatility Over Time: ONCT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 29 | Jim Breitmeyer | www.oncternal.com |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Oncternal Therapeutics, Inc. Fundamentals Summary
| ONCT fundamental statistics | |
|---|---|
| Market cap | US$23.57m |
| Earnings (TTM) | -US$39.48m |
| Revenue (TTM) | US$785.00k |
29.3x
P/S Ratio-0.6x
P/E RatioIs ONCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCT income statement (TTM) | |
|---|---|
| Revenue | US$785.00k |
| Cost of Revenue | US$29.75m |
| Gross Profit | -US$28.97m |
| Other Expenses | US$10.51m |
| Earnings | -US$39.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.68 |
| Gross Margin | -3,690.19% |
| Net Profit Margin | -5,029.17% |
| Debt/Equity Ratio | 0% |
How did ONCT perform over the long term?
See historical performance and comparison